Form 4: Alnylam CEO Greenstreet Reports Equity Grants, Tax-Related Sales

Alnylam Pharmaceuticals CEO Yvonne Greenstreet reported new equity awards, including restricted stock units, stock options, and performance stock units, alongside sales of shares to cover tax obligations.

Summary

• Yvonne Greenstreet, CEO and Director of Alnylam Pharmaceuticals, Inc., reported transactions on March 2, 2026.
• Acquired 13,844 Restricted Stock Units (RSUs), which will vest over a three-year period, with one-third vesting on each of the first, second, and third anniversaries of the grant date.
• Acquired 30,425 stock options with an exercise price of $325.07, which will vest 25% on the first anniversary of the grant date and the remaining shares in equal installments at the end of each successive three-month period thereafter until the fourth anniversary.
• Acquired 110,746 maximum Stock Price Performance Units (PSUs), with a target of 55,373 units, vesting on December 31, 2029, contingent on the achievement of pre-set stock price thresholds.
• Disposed of a total of 6,700 shares of common stock through multiple transactions at weighted average prices ranging from $323.62 to $332.64.
• These dispositions were automatic "sell-to-cover" transactions to satisfy minimum statutory tax withholding obligations related to equity awards.
• Following these transactions, Greenstreet directly beneficially owns 98,628 shares and indirectly owns 407 shares through a managed 401(k) account.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as it reflects routine executive compensation, including significant performance-based awards, which aligns management's interests with long-term shareholder value, despite the expected tax-related share sales.

Positives

• Grant of 13,844 Restricted Stock Units (RSUs) aligns executive incentives with long-term shareholder value.
• Grant of 30,425 stock options provides potential upside for the executive if the stock price increases above the $325.07 exercise price.
• Grant of up to 110,746 Stock Price Performance Units (PSUs) ties a significant portion of executive compensation directly to the achievement of pre-set stock price thresholds, incentivizing strong stock performance.
• The 401(k) matching contribution program indicates a benefit for employees, including the reporting person.

Negatives

• The disposition of 6,700 shares of common stock, totaling approximately $2.19 million based on average prices, represents a reduction in direct beneficial ownership.
• While for tax purposes, these sales reduce the executive's direct equity stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that the grant of significant equity awards, including RSUs, stock options, and performance-based units, is a standard practice in the biotechnology and pharmaceutical industry for executive compensation. This structure aims to align executive incentives with long-term shareholder value creation and company performance, particularly in a sector where innovation and stock price appreciation are key drivers.

Comparison to Industry Standards

• StockSavvy.ai observes that the mix of time-based RSUs, stock options, and performance-based PSUs is consistent with best practices in executive compensation within the biotech industry.
• Companies like Regeneron Pharmaceuticals and Vertex Pharmaceuticals often utilize similar multi-faceted equity compensation plans to attract and retain top talent, linking a substantial portion of executive pay to both time-based service and performance metrics.
• The inclusion of stock price performance units (PSUs) with a long vesting horizon (December 2029) and a wide earning range (50% to 200% of target) is a robust mechanism to incentivize sustained stock appreciation, a common feature in high-growth sectors.

Stakeholder Impact

• Shareholders: The equity grants, particularly the performance-based units, align the CEO's incentives with shareholder value creation, potentially benefiting shareholders if stock price targets are met. The tax-related sales are a routine part of executive compensation.
• Employees: The mention of the 401(k) matching contribution program suggests a broader employee benefit, though the filing focuses on the CEO's transactions.

Next Steps

• RSUs will vest over a three-year period, with one-third vesting on each of the first, second, and third anniversaries of the grant date (March 2, 2026).
• Stock options will vest as to 25% on the first anniversary of the grant date (March 2, 2026) and the remaining shares in equal installments at the end of each successive three-month period thereafter until the fourth anniversary.
• Performance Stock Units (PSUs) will vest on December 31, 2029, contingent on the achievement of pre-set stock price thresholds during the six months preceding the vesting date.

Key Dates

Recommendation

The Form 4 filing details routine executive compensation grants and associated tax-related share sales. While the grants align management incentives with long-term performance, these transactions are standard and do not provide new fundamental information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than these specific insider transactions.

Keywords

Alnylam Pharmaceuticals, ALNY, Yvonne Greenstreet, CEO, Director, SEC Form 4, Insider Trading, Restricted Stock Units, RSUs, Stock Options, Performance Stock Units, PSUs, Equity Compensation, Executive Compensation, Stock Sales, Tax Withholding